Anticoagulation Forum/LinkedIn
Jun 22, 2026, 15:08
Apixaban vs. Rivaroxaban in Acute VTE – Uncoiling COBRRA and Its Clinical Implications – Anticoagulation Forum
Anticoagulation Forum shared a post on LinkedIn:
“Recording now available!
We are grateful to our expert faculty for sharing their time, and their thoughtful discussions, and insights during our recent webinar:
Apixaban vs. Rivaroxaban in Acute VTE: Uncoiling COBRRA and Its Clinical Implications
This session explored the clinical questions behind the COBRRA trial, including retrospective evidence, potential pharmacologic explanations, study design, key findings, and practical implications for frontline VTE care.
Faculty:
- Arthur Allen, PharmD
- Lana Castellucci, MD
- Steven Deitelzweig, MD
- Jori May, MD
If you missed the live webinar, want to revisit the discussion, or know a colleague who may benefit, the recording is available to watch for free on our Archived Webinars page.
-
Jun 22, 2026, 16:45Shivangi Harankhedkar: Gene Therapy and CRISPR Advances in Hemoglobinopathies
-
Jun 22, 2026, 16:39Vikram Sinai Talaulikar: Haematology and Female Hormone Health Intersect at Multiple Levels
-
Jun 22, 2026, 16:35Sehrish Chaudhary: Advancing Transfusion Medicine Through Global Collaboration at ISBT 2026
-
Jun 22, 2026, 15:54Ready to Build Your ISTH 2026 Schedule?
-
Jun 22, 2026, 15:36Wolfgang Miesbach: What the Latest Gene Therapy Setbacks Mean for Haemophilia Care
-
Jun 22, 2026, 15:26Suvro Sankha Datta: Advancing Transfusion Medicine Through the Establishment of a Red Cell Genotyping Facility
-
Jun 22, 2026, 14:41Ilkin Aygun Soyalp: Novel Substrate Recognition Broadens the Biological Role of DPF-3
-
Jun 22, 2026, 14:29Swarnava Roy: Linking Angiotensin Signaling to Oxidative Stress and Organ Damage in Sickle Cell Anemia
-
Jun 22, 2026, 14:14Nicolò Vianini: New Evidence Confirms Bone Marrow as the Primary Site of Thrombopoiesis